Diagnostics company 20/20 GeneSystems presented data last week showing high sensitivity and specificity for its protein biomarker test to predict response to Herceptin (trastuzumab) in HER2-positive breast cancer patients.

With the support of a $3 million Small Business Innovative Research grant from the National Cancer Institute, the company is developing several theranostic and companion diagnostic tests focusing on the mTOR and VEGF pathways using its proprietary layered immunochemistry platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.